Standout Papers

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type ... 2009 2026 2014 2020 7.8k
  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
    Bernard Zinman, Christoph Wanner et al. New England Journal of Medicine
  2. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  3. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
    Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine
  4. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  5. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control (2009)
    Etie S. Moghissi, Mary T. Korytkowski et al. Diabetes Care
  6. Oral Antihyperglycemic Therapy for Type 2 Diabetes (2002)
    Silvio E. Inzucchi JAMA
  7. Mechanism by which metformin reduces glucose production in type 2 diabetes. (2000)
    Ripudaman S. Hundal, Martin Krššák et al. Diabetes
  8. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  9. How Do We Define Cure of Diabetes? (2009)
    John B. Buse, Sonia Caprio et al. Diabetes Care
  10. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus (1998)
    Silvio E. Inzucchi, David Maggs et al. New England Journal of Medicine
  11. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects (2004)
    Frans J.Th. Wackers, Lawrence H. Young et al. Diabetes Care
  12. The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes (2002)
    Adam B. Mayerson, Ripudaman S. Hundal et al. Diabetes
  13. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetologia
  14. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
    Silvio E. Inzucchi, Bernard Zinman et al. Diabetes Care
  15. Impaired Glucose Transport as a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes (1999)
    Gary W. Cline, Kitt Falk Petersen et al. New England Journal of Medicine
  16. Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes (2009)
    Lawrence H. Young, Frans J. Th. Wackers et al. JAMA
  17. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials (2022)
    Muthiah Vaduganathan, Kieran F. Docherty et al. The Lancet
  18. Metformin in Patients With Type 2 Diabetes and Kidney Disease (2014)
    Silvio E. Inzucchi, Kasia J. Lipska et al. JAMA
  19. Metformin: clinical use in type 2 diabetes (2017)
    Elizabeth Sanchez‐Rangel, Silvio E. Inzucchi Diabetologia
  20. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (2017)
    Christoph Wanner, John M. Lachin et al. Circulation
  21. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial (2017)
    David Z.I. Cherney, Bernard Zinman et al. The Lancet Diabetes & Endocrinology
  22. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  23. Empagliflozin in Heart Failure (2020)
    Matthew D. Griffin, Veena S. Rao et al. Circulation
  24. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors (2018)
    Hiddo J.L. Heerspink, Mikhail Kosiborod et al. Kidney International
  25. A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF) (2019)
    John J.V. McMurray, David L. DeMets et al. European Journal of Heart Failure
  26. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2019)
    David Fitchett, Silvio E. Inzucchi et al. Circulation
  27. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial (2021)
    Scott D. Solomon, Rudolf A. de Boer et al. European Journal of Heart Failure
  28. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction (2021)
    David D. Berg, Pardeep S. Jhund et al. JAMA Cardiology
  29. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF (2021)
    James P. Curtain, Kieran F. Docherty et al. European Heart Journal
  30. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice (2022)
    Lama Ghazi, Yu Yamamoto et al. Journal of the American College of Cardiology
  31. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025)
    Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine

Immediate Impact

11 from Science/Nature 163 standout
Sub-graph 1 of 12

Citing Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
2 intermediate papers

Works of Silvio E. Inzucchi being referenced

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
2024
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
2022 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Silvio E. Inzucchi 31183 11756 8879 13215 406 42.8k
Darren K. McGuire 24831 10353 13589 9504 456 38.4k
Lawrence A. Leiter 22573 13843 7456 9257 535 38.1k
Bernard Zinman 43046 17578 8689 18193 643 61.2k
Rury R. Holman 28999 9037 5597 10634 347 39.3k
Ele Ferrannini 28308 13056 6815 14917 523 50.0k
Peter Rossing 22306 7288 10480 8283 737 39.4k
James R. Sowers 14251 6310 15126 9747 681 41.2k
Marja‐Riitta Taskinen 23571 16228 11279 8529 565 44.3k
Mark E. Cooper 17386 5789 12490 11408 506 47.5k
Markku Laakso 22794 11434 12751 15999 667 56.6k

All Works

Loading papers...

Rankless by CCL
2026